Generate Biomedicines, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GENB research report →
Range $22 – $30
Price Chart
About the company
Generate Biomedicines, Inc. is a U. S.
- CEO
- Michael T. Nally
- IPO
- 2026
- Employees
- 312
- HQ
- Somerville, MA, US
Get TickerSpark's AI analysis on GENB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.84B
- P/E
- -13.20
- PEG
- -0.13
- P/S
- 132.47
- P/B
- 3.93
- EV/EBITDA
- -13.80
- Div Yield
- 0.00%
- Gross Margin
- 75.82%
- Op Margin
- -1002.56%
- Net Margin
- -950.66%
- ROE
- -108.80%
- ROIC
- -26.17%
Latest fiscal year · YoY change
- Revenue
- $31.89M+55.9%
- Gross Profit
- $31.89M+55.9%
- Op Income
- $-235,065,000
- Net Income
- $-203,154,000-16.9%
- EPS
- $-4.98-196.4%
- OCF Growth
- -70.4%
- FCF Growth
- -68.4%
- 52W High
- $22.67
- 52W Low
- $11.00
- 50D MA
- $15.51
- 200D MA
- $14.15
- Beta
- -0.14
- RSI (14)
- 40
- Avg Volume
- 1.05M
No earnings-call transcripts are available for GENB yet.
- Free Float
- 42.9%
- Shares Outstanding
- 128.19M
- Float Shares
- 55.05M
of shares held by institutions
58 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Flagship Pioneering Inc. | 62.67M | 0 |
| Fmr LLC | 5.22M | ▲ 1.00M |
| Capital World Investors | 4.22M | ▲ 211.48K |
| Braidwell LP | 3.28M | ▼ 309.15K |
| Price T Rowe Associates Inc | 2.16M | ▲ 46.99K |
| Norges Bank | 2.09M | ▲ 2.09M |
| Arch Venture Management, LLC | 1.94M | 0 |
| Harbourvest Partners LLC | 1.72M | 0 |
| Blackrock, Inc. | 1.66M | ▲ 1.66M |
| Baker Bros. Advisors LP | 1.42M | 0 |
| Jpmorgan Chase & Co | 1.41M | ▼ 1.54M |
| Deep Track Capital, LP | 1.33M | ▲ 1.33M |
Held by 99 ETFs
Biggest fund positions in GENB by dollar value.
Our GENB coverage
Recent articles, reports, and earnings notes.
No research on GENB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GENB report →Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Generate Biomedicines (NASDAQ:GENB)
defenseworld.net · Oct 4
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer
globenewswire.com · Oct 1
Squarepoint Ops LLC Makes New $530,000 Investment in Generate Biomedicines Inc $GENB
defenseworld.net · Sep 21
Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 14
Generate Biomedicines Inc. to Participate in September Investor Conferences
globenewswire.com · Sep 8
Generate Biomedicines stock jumps as post-IPO lock-up set to expire
proactiveinvestors.com · Aug 25
Generate Biomedicines stock jumps as post-IPO lock-up set to expire
proactiveinvestors.com · Aug 25
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.